High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomi...
High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
Subjects
More information
Scope and Contents
Contents
PurposeToxic shock syndrome (TSS) is a rare disease responsible for significant morbidity and mortality. Intravenous immunoglobulin (IG) therapy in paediatric TSS could improve shock and organ failure, but more consistent efficacy and safety data are needed. Our objective was to determine whether a randomised clinical trial (RCT) assessing intraven...
Alternative Titles
Full title
High-dose intravenous immunoglobulin versus albumin 4% in paediatric toxic shock syndrome: a randomised controlled feasibility study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11347220
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11347220
Other Identifiers
ISSN
0003-9888,1468-2044
E-ISSN
1468-2044
DOI
10.1136/archdischild-2022-325274
